2022 Annual Meeting | C153 - Neurogenetics: Diagnostic Dilemmas and Therapeutic Implications

Date Thursday 04/07/22

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jacinda B. Sampson, MD, PhD

Topic(s) General Neurology

Learning Objectives Participants should be able to recognize and manage pediatric and adult neurogenetic diagnostic dilemmas, and become familiar with therapeutic implications and breakthroughs in the field.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:45 AM PDT	Speaker	Cases (and Lessons) from a Pediatric Neurogenomics Clinic Maura R. Ruzhnikov, MD
07:00 AM - 07:00 AM PDT	Speaker	Walk-in Slides Jacinda B. Sampson, MD, PhD
07:45 AM - 08:00 AM PDT	Q&A	Questions and Answers Maura R. Ruzhnikov, MD
08:00 AM - 08:45 AM PDT	Speaker	Adult Cases in Neurogenetics: Dilemmas and Therapeutic Options Jacinda B. Sampson, MD, PhD
08:45 AM - 09:00 AM PDT	Q&A	Questions and Answers Jacinda B. Sampson, MD, PhD

Faculty Disclosures
Jacinda B. Sampson, MD, PhD	Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viking Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sampson has received research support from Marigold Foundation. Dr. Sampson has a non-compensated relationship as a Scientific Advisory Committee with Myotonic Dystrophy Foundation that is relevant to AAN interests or activities.
Maura R. Ruzhnikov, MD	Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orchard Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Travere Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapetuics. The institution of Dr. Ruzhnikov has received research support from Grace Science Foundation. The institution of Dr. Ruzhnikov has received research support from Ionis Pharmaceuticals. The institution of Dr. Ruzhnikov has received research support from NIH. Dr. Ruzhnikov has a non-compensated relationship as a Co-founder and Secretary with Little Zebra Fund that is relevant to AAN interests or activities.